FY2025 EPS Forecast for Travere Therapeutics Cut by Analyst

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Travere Therapeutics in a report issued on Wednesday, June 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($0.70) per share for the year, down from their previous estimate of ($0.67). The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Travere Therapeutics' FY2026 earnings at $0.21 EPS.

Several other research firms also recently weighed in on TVTX. Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a report on Wednesday, April 23rd. HC Wainwright raised Travere Therapeutics to a "buy" rating and set a $30.00 price target on the stock in a report on Wednesday, June 11th. Canaccord Genuity Group boosted their price target on Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Stifel Nicolaus increased their price objective on Travere Therapeutics from $22.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, May 2nd. Finally, Scotiabank reissued an "outperform" rating on shares of Travere Therapeutics in a report on Friday, April 11th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Travere Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $32.14.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX traded up $0.32 during trading hours on Monday, reaching $14.41. The stock had a trading volume of 1,951,900 shares, compared to its average volume of 1,623,838. The firm has a 50-day moving average of $16.88 and a 200-day moving average of $18.44. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -5.13 and a beta of 0.75. The company has a current ratio of 2.05, a quick ratio of 2.03 and a debt-to-equity ratio of 9.46. Travere Therapeutics has a fifty-two week low of $6.80 and a fifty-two week high of $25.29.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.08. The firm had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. Travere Therapeutics's quarterly revenue was up 83.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.76) earnings per share.

Insiders Place Their Bets

In other news, CFO Christopher R. Cline sold 1,784 shares of Travere Therapeutics stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,553.20. Following the completion of the sale, the chief financial officer now directly owns 93,126 shares in the company, valued at approximately $1,960,302.30. This trade represents a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric M. Dube sold 18,924 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the transaction, the chief executive officer now directly owns 419,173 shares of the company's stock, valued at $8,823,591.65. The trade was a 4.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,527 shares of company stock worth $473,814. Corporate insiders own 4.19% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in Travere Therapeutics during the 4th quarter valued at about $31,000. Sterling Capital Management LLC grew its position in shares of Travere Therapeutics by 859.8% in the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock valued at $41,000 after purchasing an additional 2,115 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Travere Therapeutics during the 1st quarter worth approximately $62,000. Gen Wealth Partners Inc acquired a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $73,000. Finally, KBC Group NV purchased a new stake in Travere Therapeutics in the 1st quarter valued at approximately $75,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.